Detection method for n-nitrosodimethylamine impurities

Patent metadata

Field	Value
Publication number	US-11519890-B2
Application number	US-201817258226-A
Country	US
Kind code	B2
Filing date	Jul 10, 2018
Priority date	Jul 7, 2018
Publication date	Dec 6, 2022
Grant date	Dec 6, 2022

Abstract

Disclosed is a detection method for N-nitrosodimethylamine (NDMA) impurities, comprising: (1) obtaining a test solution containing a sample to be tested; and (2) detecting the test solution by means of gas chromatography-mass spectrometry to determine the content of an N-nitrosodimethylamine impurity in the sample. The method provided in the present invention has a good separating effect, a wide linear range, a high sensitivity and a good method durability, and can detect the content of N-nitrosodimethylamine (NDMA) in the sample rapidly and effectively.

First claim

The invention claimed is:

1. A method for detecting N-nitrosodimethylamine impurity by gas chromatography-mass spectrometry, wherein the method comprises the following steps:
(1) dissolving a sample to be detected which is suspected to contain N-nitrosodimethylamine impurity in a diluent to prepare a test solution, wherein the sample to be detected is a sartan active pharmaceutical ingredient (API) intermediate, a solvent used in a synthesis process of a sartan API, a sartan API or a composition containing a sartan API, the solvent is injected directly without diluent; and
(2) transferring the prepared test solution to an injection vial or headspace bottle, and analyzing the solution in the injection vial or headspace bottle by gas chromatography-mass spectrometry to determine the content of N-nitrosodimethylamine impurity in the sample.

2. The method according to claim 1 , wherein step (2) comprises: injecting the test solution into the gas chromatography-mass spectrometry for detection, recording a spectrum of the test solution, and determining the content of N-nitrosodimethylamine in the sample to be detected according to a standard curve of N-nitrosodimethylamine obtained in advance.

3. The method according to claim 1 , wherein the sample to be detected is a sartan API intermediate, a solvent used in a synthesis process of a sartan API, a sartan API or a composition containing a sartan API.

4. The method according to claim 1 , wherein:
when the sample to be detected is a sartan API intermediate or sartan API, the sample to be detected is dissolved in a diluent to obtain the test solution;
when the sample to be detected is a composition containing a sartan API, the composition containing the sartan API is disintegrated with the diluent to obtain the test solution; or
when the sample to be detected is a solvent used in a synthesis process of a sartan API, the solvent is directly used as the test solution.

5. The method according to claim 1 , wherein the method comprises the following steps:
(1) when the sample to be detected is a sartan API intermediate or sartan API, dissolving the sartan API intermediate or sartan API in a diluent, and preparing the test solution containing 1-5000 mg of the sartan API intermediate or sartan API in 1 mL of the test solution;
when the sample to be detected is a composition containing a sartan API, disintegrating the composition containing the sartan API in a diluent, and preparing the test solution containing 1-5000 mg of the sartan API in 1 mL of the test solution; or
when the sample to be detected is a solvent used in a synthesis process of a sartan API, directly using the solvent as the test solution; and
(2) injecting the test solution into the gas chromatography-mass spectrometry for detection, recording the spectrum of the test solution, and determining the content of N-nitrosodimethylamine in the sample according to a standard curve of N-nitrosodimethylamine obtained in advance.

6. The method according to claim 4 , wherein the diluent is selected from the group consisting of water, and a polar organic solvent, or a mixture thereof.

7. The method according to claim 1 , wherein the gas chromatography-mass spectrometry is operated under the following conditions:
a chromatographic column: a gas chromatographic column, wherein the stationary phase is composed of one selected from the group consisting of polysiloxane polymer, cyanopropylphenyl dimethylpolysiloxane copolymer, cyanopropyl dimethylpolysiloxane copolymer, trifluoropropyl dimethylpolysiloxane copolymer, phenyl dimethylpolysiloxane copolymer, dipropylphenyl dimethylpolysiloxane copolymer, diphenyl dimethylpolysiloxane copolymer, and polyethylene glycol or any combination thereof;
a carrier gas selected from the group consisting of hydrogen, nitrogen and helium;
a column temperature: 30° C.-350° C.;
a split ratio: 1:1-500:1;
an inlet temperature: 100° C.-350° C.;
an injection mode: a direct injection or headspace injection; and
a detector: a mass spectrometry detector.

8. The method according to claim 7 , wherein the stationary phase of the gas chromatographic column is composed of 14% cyanopropylphenyl-86% dimethylpolysiloxane copolymer, 35% phenyl-65% dimethylpolysiloxane copolymer, 5% phenyl-95% dimethylpolysiloxane copolymer, 6% cyanopropyl-94% dimethylpolysiloxane copolymer, 7% cyanopropyl-7% phenyl-86% dimethylpolysiloxane copolymer, 50% cyanopropyl-50% dimethylpolysiloxane copolymer, 5% cyanopropyl-95% dimethylpolysiloxane copolymer or polyethylene glycol having a molecular weight of 10,000-1,000,000.

9. The method according to claim 7 , wherein the mass spectrometry detector is selected from the group consisting of a single quadrupole mass spectrometer, a quadrupole-time-of-flight mass spectrometer and a triple quadrupole mass spectrometer.

10. The method according to claim 3 , wherein the sartan API is selected from the group consisting of a compound shown in Formula I:

wherein R 1 represents

R 3 represents H or K.

11. The method according to claim 3 , wherein the sartan API is selected from the group consisting of Losartan potassium, Irbesartan and Valsartan.

12. The method according to claim 3 , wherein the sartan API intermediate is selected from the group consisting of a compound shown in the Formula II:

wherein R 1 represents

13. The method according to claim 5 , wherein when the sample to be detected is the sartan API intermediate or sartan API, the sartan API intermediate or sartan API is dissolved in the diluent, and the test solution containing 1-1000 mg of the sartan API intermediate or sartan API in 1 mL of the test solution is prepared; or
when the sample to be detected is the composition containing the sartan API, the composition containing the sartan API is disintegrated in the diluent, and the test solution containing 1-1000 mg of the sartan API in 1 mL of the test solution is prepared.

14. The method according to claim 5 , wherein when the sample to be detected is the sartan API intermediate or sartan API, the sartan API intermediate or sartan API is dissolved in the diluent, and the test solution containing 5-200 mg of the sartan API intermediate or sartan API in 1 mL of the test solution is prepared; or
when the sample to be detected is the composition containing the sartan API, the composition containing the sartan API is disintegrated in the diluent, and the test solution containing 5-500 mg of the sartan API in 1 mL of the test solution is prepared.

15. The method according to claim 5 , wherein when the sample to be detected is the composition containing the sartan API, the composition containing the sartan API is disintegrated in the diluent, and the test solution containing 5-30 mg of the sartan API in 1 mL of the test solution is prepared.

16. The method according to claim 6 , wherein the polar organic solvent is one selected from the group consisting of N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, methanol, ethanol, isopropanol, acetone, methyl tert-butyl ether, acetonitrile, ethylene glycol, propanediol, glycerol, formic acid, acetic acid, propionic acid, methanesulfonic acid, triethylamine, d

Assignees

• Zhejiang Huahai Pharm Co Ltd

Inventors

• Xiao Tan
• Huang Tianpei
• Lin Jinsheng
• Zhou Qiang
• Wu Tong
• Ye Danfeng
• Cai Hong
• Zhu Wenquan
• Chen Wenbin
• Li Min

Classifications

• G01N30/7206 Primary

  interfaced to gas chromatograph (interfaces in general for introducing or extracting samples to be analysed with specially adapted mass spectrometer, see H01J49/04) · CPC title

• G01N30/88 Primary

  Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 · CPC title

• G01N2030/067

  by reaction, e.g. derivatising the sample · CPC title

• G01N2030/8872

  impurities · CPC title

• G01N2030/884

  organic compounds · CPC title